Equities analysts forecast that INmune Bio Inc (NASDAQ:INMB) will announce earnings per share of ($0.20) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for INmune Bio’s earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.21). The company is expected to announce its next earnings results on Monday, November 11th.
On average, analysts expect that INmune Bio will report full-year earnings of ($0.65) per share for the current financial year, with EPS estimates ranging from ($0.68) to ($0.61). For the next year, analysts expect that the business will report earnings of ($0.87) per share, with EPS estimates ranging from ($0.99) to ($0.75). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for INmune Bio.
INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.16.
INmune Bio stock remained flat at $$6.20 during mid-day trading on Friday. The company had a trading volume of 5,587 shares, compared to its average volume of 20,736. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.94 and a current ratio of 20.94. INmune Bio has a 12 month low of $5.06 and a 12 month high of $11.50. The firm’s 50-day simple moving average is $6.88 and its 200-day simple moving average is $8.82.
In other news, Director Scott Juda acquired 5,000 shares of INmune Bio stock in a transaction that occurred on Wednesday, August 21st. The stock was bought at an average price of $6.00 per share, for a total transaction of $30,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have purchased 12,000 shares of company stock valued at $72,990. 67.67% of the stock is owned by company insiders.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. grew its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,048 shares of the company’s stock after buying an additional 2,864 shares during the quarter. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 as of its most recent SEC filing. 0.36% of the stock is currently owned by hedge funds and other institutional investors.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
See Also: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.